Listerine meeting postponed
This article was originally published in The Tan Sheet
"Feedback" meeting on Pfizer's proposed changes to the OTC anticaries final monograph, originally slated for June 18, will be rescheduled within a month to give Division of OTC Drug Products more time to review relevant material, FDA says June 14. Meeting is part of Pfizer's efforts to amend monograph to allow for a mouthrinse combining essential oils, sodium fluoride (1"The Tan Sheet" June 10, 2002, p. 3)...
You may also be interested in...
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.